返回 Agenda
Session 5: Clarity in Clinical Trials
Session Chair(s)
Francine Lane, MBA
Senior Director of Product Management
Citeline, United States
This comprehensive session explores the critical role of Plain Language Summaries (PLS) in clinical trial disclosure, addressing the EU CTR requirement and global best practices. Attendees will gain insights into developing effective summaries that adhere to health literacy principles, navigate regulatory requirements, and overcome common challenges in the field. The session will also delve into the value of plain language writing in clinical research operations and explore the patient perspective plain-language summaries.
Learning Objective : - Develop a toolkit of industry-proven strategies for crafting Plain Language Summaries (PLS)
- Explain key challenges in maintaining consistency and protecting participant privacy when reporting clinical trial endpoints and safety data in plain language formats
- Identify and evaluate the primary sources where patients find and access clinical trial information
Speaker(s)
The Value of Plain Language Writing in Clinical Research Operations and Medical Communication
Oladayo Oyelola, PhD
Daiichi Sankyo, Inc. , United States
Senior Director and Head Global Clinical Trial Information Disclosure
Navigating EU CTR: Mastering Effective Lay Protocol Synopses (LPS) and Plain Language Summary (PLS) Development
Maureen Kashuba, BSN
Merck Sharp & Dohme LLC, United States
Assoc. Director, Plain Language Summaries Program Lead
PLS Strategies That Work for Patients, Sites, & Sponsors
Deborah Collyar
Patient Advocates In Research (PAIR), United States
President